European life science companies face a relative lack of capital compared to US companies. This gap engenders differing styles of investment and exit opportunities in Europe that can have meaningful implications for business plans and execution differences between the two continents.
Read MoreThe underlying premise at Back Bay Life Science Advisors is that any accurate asset or company valuation must be derived from a fundamental understanding of the scientific, clinical, and commercial aspects of the financial models in use.
Read More